Can a pill clear the toxic proteins behind Alzheimer's?

NCT ID NCT07741526

Ongoing Disease control Sponsor: Arctic Therapeutics Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called NPI-001 in people aged 50 to 85 with mild cognitive impairment or mild Alzheimer's disease. Participants take either the drug or a placebo as tablets twice daily for 12 months, with doses increasing over time. The study measures safety and whether the drug reduces harmful amyloid proteins and other Alzheimer's-related biomarkers in the blood. It aims to see if NPI-001 can slow the disease process at an early stage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NPI-001 (AT-001) tablets taken by mouth twice daily
What this could lead to: If successful, this could point toward a treatment that slows or halts Alzheimer's-related brain damage by targeting toxic protein clumps.
What could go wrong: This is an early, small trial focused on safety and biomarkers, not proof of clinical benefit. The drug may not show meaningful effects or could cause side effects like brain swelling (ARIA).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

Landspitali University Hospital

Reykjavik, 108, Iceland
Sanos Clinic Gandrup

Gandrup, Denmark
Sanos Clinic Herlev

Herlev, Denmark
Sanos Clinic Vejle

Vejle, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.